Cargando…
Serum sickness following rituximab therapy in a patient with pemphigus vulgaris: A case report
Serum sickness, a reaction presenting with a classic triad (fever, rash, myalgia/arthralgia), is considered as a rare adverse event following monoclonal antibodies and specifically following treatment with rituximab. This report describes a case of serum sickness in a newly treated young male patien...
Autores principales: | Khatib, Mohamad Y., Allafi, Solaiman M., Nashwan, Abdulqadir J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7869366/ https://www.ncbi.nlm.nih.gov/pubmed/33598239 http://dx.doi.org/10.1002/ccr3.3642 |
Ejemplares similares
-
Rituximab in the Treatment of Pemphigus Vulgaris
por: Zakka, Labib R., et al.
Publicado: (2012) -
Rituximab therapy improves recalcitrant Pemphigus vulgaris
por: Noormohammadpour, Pedram, et al.
Publicado: (2015) -
AZD-1222/rituximab: Pemphigus vulgaris and pemphigus vulgaris flare-up: 2 case reports
Publicado: (2022) -
Rituximab: Aggressive course of pemphigus vulgaris: case report
Publicado: (2021) -
Pemphigus vulgaris successfully treated with ocrelizumab following rituximab allergy
por: Benesh, Gabrielle, et al.
Publicado: (2021)